Company Spotlight: Ibex Galen Second Read - Catching Missed Prostate Cancer

We unpack the FDA 510(k) summary for Galen Second Read by Ibex Medical Analytics. This episode explores how this cloud-hosted AI acts as a background safety net for pathologists, analyzing prostate biopsies initially diagnosed as benign to catch missed cancers, and what the real-world trade-offs in specificity look like.

Key points

• Galen Second Read is cleared as a Class II software algorithm device to assist users in digital pathology.
• It operates in the background specifically on prostate core needle biopsies initially diagnosed as benign by a pathologist.
• In a retrospective clinical study of cases initially diagnosed as benign, pathologists using the software achieved a sensitivity of 36.3%, catching cancers that would have otherwise been missed.
• The safety-net approach comes with a trade-off: overall specificity decreased by 3.2% when pathologists used the device compared to standard of care.
• The software is cloud-hosted, requires a minimum 20 Mbps internet connection, and is currently cleared for use with the Philips Ultra Fast Scanner.

Source: FDA 510(k) summary K241232: Galen™ Second Read™ (Ibex Medical Analytics) - U.S. Food and Drug Administration, 2025

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Ibex Medical Analytics (ibex-ai.com) · Product: Galen™ Second Read™ · FDA 510(k) K241232

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-ibex-galen-second-read-catching-missed-prostate-canc-9b7841